Clinical trials are becoming more sophisticated, global, and operationally demanding. Sponsors need technology and teams that can keep pace. Suvoda empowers organizations to execute their complex trials with confidence.
Complexity is not inherently negative. In many cases, it reflects more targeted therapies, adaptive designs, and more ambitious scientific questions. But without the right planning and infrastructure, complexity can introduce risk. Managing today's trials requires technology and teams fully equipped to respond to complexity.
4 types of clinical trial complexity
Adaptive designs, multi-arm studies, intricate dosing, mid-study changes
At least 1 substantial amendment
Multiple treatment arms
4× growth
of multi-arm, multi-stage trials from 2019–20202
What trials need
Technology that translates protocol logic into clear steps for patients, sites, and sponsors
Global sites, supply logistics, extended timelines
15–20%
biologics use in clinical trials in 20223
A significant jump from 2010, when biologics comprised 10–15% of all clinical trials
1 year longer
Phase III clinical trial duration has grown3
From about 2.25 years in 2010 to 3.25 years in 2021
What trials need
Real-time oversight of supply and study operations
Trade disruption, regional conflict, pandemics
79%
of studies were affected by COVID-19 in 20204
300+
studies running in Ukraine as of May 20245
Trial integrity and patient access in jeopardy due to war
What trials need
Operational resilience and flexible supply planning
Heavier visit schedules, financial pressure, enrollment barriers
61%
growth in Phase III protocol procedures over a 10-year period6
49%
of clinical trial participants said traveling to the study clinic was disruptive7
What trials need
Systems and services that reduce barriers to patient participation
Suvoda combines flexible technology with experienced service teams to help sponsors manage complexity and keep trials running smoothly.
The patented Suvoda Platform connects patient, site, and study data through a single, synchronous data layer across all solutions. This creates a unified, real-time view of the trial in one place, reducing the need to reconcile data across systems. With centralized reporting and configurable dashboards, teams can quickly access key metrics, monitor trends, and make informed decisions with confidence in the integrity of their data.
Complex trials require sophisticated study designs from the start. Intricate randomization logic, complex supply rules, and study-specific configurations must be precise. Suvoda applies agentic AI to accelerate the build process, helping teams translate complex protocol requirements into customized study setups faster. And when trials evolve mid-study, that same AI capability helps teams respond without losing momentum. Sofia, Suvoda's AI assistant, then gives study teams a direct line of sight to operational information—supply levels, site status, study performance, and more—through a simple conversation that supports timely, well-governed decisions.
Suvoda brings key trial activities—such as Suvoda eCOA, Suvoda RTSM, Suvoda eConsent, Greenphire Patient Payments, and Greenphire Travel—together within one platform. Our user-centered technology reduces fragmentation and duplicate data entry for sites, while simplifying how patients interact with the study through the Suvoda App. The result is a more consistent, manageable experience that supports participation and reduces administrative burden.
Technology alone does not manage the realities of complex trials. Suvoda's service teams partner with sponsors and CROs throughout the study, drawing on experience with intricate protocols and thousands of global trials. By incorporating feedback and adapting to changing needs, they help identify risks early and maintain stability as conditions evolve.
| |
One-sheet Take this with you as a PDFDownload PDF |
1 Miessler J. No end in sight for trial complexity, CSDD report reveals. CenterWatch. January 2022.
2 Noor NM, Pett SL, Esmail H, et al. Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials. BMJ Open. 2022.
3 Culbertson J. Clinical trial duration trends and the study closeout gap. Clinical Leader. June 14, 2022.
4 Roberts MB. The impact of COVID-19 on clinical research in the life sciences industry: is there a silver lining? Maynard Nexsen. 2021.
5 State Expert Center, Ministry of Health of Ukraine. Reference Information on the Clinical Trial Status in Ukraine for the Period from 01 January 2024 until 31 December 2024. Kyiv: State Expert Center; 2025.
6 Society for Clinical Research Sites. 2025 SCRS Landscape Survey Report. SCRS; 2025.
7 Center for Information and Study on Clinical Research Participation. Perceptions & Insights Study 2025. CISCRP; 2025.